Medicare Part B Meeting, 340B Implications
MedPAC, a group advising Congress on Medicare issues, held a vote on 3 recommendations to reduce prices for accelerated approval drugs covered under Medicare Part B; David Balat, Healthcare Policy Director for the Texas Public Policy Foundation, says...
MedPAC, a group advising Congress on Medicare issues, held a vote on 3 recommendations to reduce prices for accelerated approval drugs covered under Medicare Part B; David Balat, Healthcare Policy Director for the Texas Public Policy Foundation, says vague language surrounding the 340B program allows it to be misused; Patients Rising Now submits comments on CMS’ Medicare Drug Price Negotiation Program Guidance; The Safe Step Act is reintroduced in the House; and Shannon Sharp is our patient correspondent from Alabama’s 2nd Congressional District who discusses copay accumulator programs.
MedPAC Webpage: April 2023 Public Meeting
Wilcox: MedPAC’s Part B Recommendations Threaten Patient Access to Care
Patients Rising Now: Medicare Drug Price Negotiation Program Guidance Memo
X-Linked Hypophosphatemia and Copay Accumulators
X-Linked Hypophosphatemia Robbed by Copay Accumulator practice
Listen On
